Last Updated: November 16, 2026

Ironwood Pharms Inc Company Profile

« Back to Dashboard


What is the competitive landscape for IRONWOOD PHARMS INC

IRONWOOD PHARMS INC has two approved drugs.

There are eight US patents protecting IRONWOOD PHARMS INC drugs.

Summary for Ironwood Pharms Inc
US Patents:8
Tradenames:2
Ingredients:2
NDAs:2

Drugs and US Patents for Ironwood Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-002 Aug 18, 2017 DISCN Yes No 8,283,369 ⤷  Start Trial ⤷  Start Trial
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 DISCN Yes No 8,546,436 ⤷  Start Trial Y ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 9,216,179 ⤷  Start Trial ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 8,084,483 ⤷  Start Trial ⤷  Start Trial
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 DISCN Yes No 9,956,205 ⤷  Start Trial ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 10,183,012 ⤷  Start Trial ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 DISCN Yes No 9,956,205 ⤷  Start Trial ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for Ironwood Pharms Inc

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-001 Aug 18, 2017 8,003,681 ⤷  Start Trial
Ironwood Pharms Inc DUZALLO allopurinol; lesinurad TABLET;ORAL 209203-002 Aug 18, 2017 8,003,681 ⤷  Start Trial
Ironwood Pharms Inc ZURAMPIC lesinurad TABLET;ORAL 207988-001 Dec 22, 2015 8,003,681 ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for Ironwood Pharms Inc Drugs

Country Patent Number Estimated Expiration
Poland 2658846 ⤷  Start Trial
Hungary E031766 ⤷  Start Trial
Eurasian Patent Organization 201270666 ⤷  Start Trial
World Intellectual Property Organization (WIPO) 2010028190 ⤷  Start Trial
Ecuador SP10010310 ⤷  Start Trial
Croatia P20140950 ⤷  Start Trial
Mexico 2011002449 ⤷  Start Trial
>Country >Patent Number >Estimated Expiration

Supplementary Protection Certificates for Ironwood Pharms Inc Drugs

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2217577 CA 2019 00003 Denmark ⤷  Start Trial PRODUCT NAME: DUZALLO - ALLOPURINOL/LESINURAD OR A PHARMACEUTICALLY ACCEPTABLE SALT OR SALTS THEREOF; REG. NO/DATE: EU/1/18/1300 20180827
2217577 201940004 Slovenia ⤷  Start Trial PRODUCT NAME: ALLOPURINOL/LESINURAD OR ITS PHARMACEUTICALLY ACCEPTABLE SALT OR SALTS; NATIONAL AUTHORISATION NUMBER: EU/1/18/1300; DATE OF NATIONAL AUTHORISATION: 20180823; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2135608 34/2016 Austria ⤷  Start Trial PRODUCT NAME: LESINURAD ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1080 (MITTEILUNG) 20160222
2217577 C20190007 00276 Estonia ⤷  Start Trial PRODUCT NAME: ALLOPURINOOL/LESINURAAD;REG NO/DATE: EU/1/18/1300 27.08.2018
2217577 2019C/502 Belgium ⤷  Start Trial PRODUCT NAME: DUZALLO - ALLOPURINOL / LESINURAD OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE OU UN DE SES SELS; AUTHORISATION NUMBER AND DATE: EU/1/18/1300 20180827
2135608 93169 Luxembourg ⤷  Start Trial PRODUCT NAME: LESINURAD , OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; FIRST REGISTRATION DATE: 20160222
2135608 2016C/039 Belgium ⤷  Start Trial PRODUCT NAME: LESINURAD, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; AUTHORISATION NUMBER AND DATE: EU/1/15/1080 20160222
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.